Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells

2017

Background/Aims: Istaroxime is a validated inotropic Na+/K+ ATPase inhibitor currently in development for the treatment of various cardiac c

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

56

References

4

Citations